Establishment of Patient-derived tumor xenograft (PDX) model and application for precision cancer medicine.

Abstract

Patient-derived xenograft (PDX) models can be created with transplantation of cancerous cells or tissues from patient’s primary tumors into immunodeficient mice. PDX technology leads to the breakthrough with the introduction of novel highly immunodeficient mice such as NOG (NOD/Scid/IL2Rγ^null), NSG (NOD/Scid/IL2Rγ^null), and NOJ (NOD/Scid/Jak3^null) mice. As PDX has been shown to conserve human original tumor characteristics, it is now getting standard methods to evaluate the drug sensitivity, and PDX library is now established in many organization with integrated genomic signature. These PDX data base are getting powerful tool for advancing Precision Cancer Medicine.